Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C Isles is active.

Publication


Featured researches published by C Isles.


Circulation | 2001

Pravastatin and the Development of Diabetes Mellitus Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

Dilys J. Freeman; John Norrie; Naveed Sattar; R. Dermot G. Neely; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Christopher J. Packard; James Shepherd; Allan Gaw

BackgroundWe examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study. Methods and ResultsOur definition of diabetes mellitus was based on the American Diabetic Association threshold of a blood glucose level of ≥7.0 mmol/L. Subjects who self-reported diabetes at baseline or had a baseline glucose level of ≥7.0 mmol/L were excluded from the analyses. A total of 5974 of the 6595 randomized subjects were included in the analysis, and 139 subjects became diabetic during the study. The baseline predictors of the transition from normal glucose control to diabetes were studied. In the univariate model, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors. In a multivariate model, body mass index, log triglyceride, glucose, and pravastatin therapy were retained as predictors of diabetes in this cohort. ConclusionsWe concluded that the assignment to pravastatin therapy resulted in a 30% reduction (P =0.042) in the hazard of becoming diabetic. By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.


Journal of Human Hypertension | 2003

Diarrhoea, vomiting and ACE inhibitors: – an important cause of acute renal failure

Cath Stirling; J. Houston; Stuart Robertson; James Boyle; A. Allan; John Norrie; C Isles

The occurrence of severe acute renal failure in 3 patients who developed diarrhoea while taking angiotensin converting enzyme (ACE) inhibitors led us to undertake a retrospective cohort survey to determine the frequency with which diarrhoea and vomiting are associated with acute renal failure in patients taking this class of drug. Serum creatinine was measured as part of the diagnostic workup of 2398 consecutive admissions to an acute medical receiving unit in a district general hospital. Outcome measures were the presence of diarrhoea and/or vomiting, and whether taking an ACE inhibitor, NSAID or diuretic at the time of admission, also previous, initial and follow up serum creatinine concentrations. Peak serum creatinine in the 3 cases was 1159, 989 and 765 μmol/l. None of the 3 required dialysis and all recovered renal function completely after receiving large volumes of intravenous fluid. In the cohort study, 89 of 2398(3.7%) admissions had serum creatinine ⩾200 μmol/l. Nine were regular dialysis patients. Of the remaining patients, 30 (37.5%) were taking an ACE inhibitor. Six of 30 (20%) gave a history of diarrhoea and/or vomiting. Median creatinine concentration in this group was 135 (range 111–209) μmol/l before admission, 292 (216–724) μmol/l when first seen in hospital, and 134 (94–219) μmol/l following the withdrawal of drug therapy and fluid replacement. In conclusion, volume depletion causing acute renal failure in patients taking ACE inhibitors is not uncommon. Such patients and their general practitioners should be aware that reversible renal impairment may occur during intercurrent illnesses, particularly if characterised by diarrhoea and/or vomiting.


Circulation | 1998

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

Christopher J. Packard; James Shepherd; Stuart M. Cobbe; Jane B. Ford; C Isles; J. H. McKillop; Peter W. Macfarlane; Ar Lorimer; John Norrie; W Scotland Coronary Prevention Study Grp


Atherosclerosis Supplements | 2004

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

James Shepherd; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Christopher J. Packard


The Lancet | 1996

West of Scotland Coronary Prevention Study

James Shepherd; Stuart M. Cobbe; Ar Lorimer; J. H. McKillop; Jane B. Ford; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; L Anderson; D Duncan; Sharon Kean; A Lawrence; J McGrath; K Montgomery; John Norrie; M Percy; E Pomphrey; A Whitehouse; P Cameron; P Parker; F Porteous; L Fletcher


European Heart Journal | 1997

Compliance and adverse event withdrawal: their impact on the west of Scotland Coronary Prevention Study

James Shepherd; Stuart M. Cobbe; Ar Lorimer; J. H. McKillop; Jane B. Ford; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; L Anderson; D Duncan; Sharon Kean; A Lawrence; J McGrath; K Montgomery; John Norrie; M Percy; E Pomphrey; A Whitehouse; P Cameron; P Parker; F Porteous; L Fletcher


American Journal of Cardiology | 1995

SCREENING EXPERIENCE AND BASE-LINE CHARACTERISTICS IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY

Sm Cobbe; Ar Lorimer; J. H. McKillop; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; John Norrie


Archive | 1995

Prevention of coronary heart disease with pravas-tatin in men with hypercholesterolemia

James Shepherd; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Chris J. Packard


Health bulletin | 2001

Haemodialysis in a rural area: a demanding form of treatment.

A. Brammah; G. Young; A. Allan; Stuart Robertson; John Norrie; C Isles


The Lancet | 1997

WOSCOPS. AUTHORS' REPLY

T. A. Barringer; C Isles; Stuart M. Cobbe; Ian Ford

Collaboration


Dive into the C Isles's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Norrie

University of Aberdeen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Allan Gaw

Glasgow Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge